Residential College | false |
Status | 已發表Published |
Codelivery of Doxorubicin and shAkt1 by Poly(ethylenimine)-Glycyrrhetinic Acid Nanoparticles to Induce Autophagy-Mediated Liver Cancer Combination Therapy | |
Feng-Zhen Wang1; Lei Xing1; Zheng-hai Tang3; Jin-Jian Lu3; Peng-Fei Cui1; Jian-Bing Qiao1; Lei Jiang1; Hu-Lin Jiang1; Li Zong1 | |
2016-04-04 | |
Source Publication | Molecular Pharmaceutics |
ISSN | 15438392 15438384 |
Volume | 13Issue:4Pages:1298-1307 |
Abstract | Combination therapy has been developed as a promising therapeutic approach for hepatocellular carcinoma therapy. Here we report a low toxicity and high performance nanoparticle system that was self-assembled from a poly(ethylenimine)-glycyrrhetinic acid (PEI-GA) amphiphilic copolymer as a versatile gene/drug dual delivery nanoplatform. PEI-GA was synthesized by chemical conjugation of hydrophobic GA moieties to the hydrophilic PEI backbone via an acylation reaction. The PEI-GA nanocarrier could encapsulate doxorubicin (DOX) efficiently with loading level about 12% and further condense DNA to form PEI-GA/DOX/DNA complexes to codeliver drug and gene. The diameter of the complexes is 102 ± 19 nm with zeta potential of 19.6 ± 0.2 mV. Furthermore, the complexes possess liver cancer targeting ability and could promote liver cancer HepG2 cell internalization. Apoptosis of cells could be induced by chemotherapy of DOX, and PI3K/Akt/mTOR signaling pathway acts a beneficial effect on the modulation of autophagy. Here, it is revealed that utilizing PEI-GA/DOX/shAkt1 complexes results in effective autophagy and apoptosis, which are useful to cause cell death. The induction of superfluous autophagy is reported to induce type-II cell death and also could increase the sensity of chemotherapy to tumor cells. In this case, combining autophagy and apoptosis is meaningful for oncotherapy. In this study, PEI-GA/DOX/shAkt1 has demonstrated favorable tumor target ability, little side effects, and ideal antitumor efficacy. |
Keyword | Autophagy Combination Therapy Glycyrrhetinic Acid Liver Cancer Targeting Self-assembled |
DOI | 10.1021/acs.molpharmaceut.5b00879 |
URL | View the original |
Indexed By | SCIE |
WOS Research Area | Research & Experimental Medicine ; Pharmacology & Pharmacy |
WOS Subject | Medicine, Research & Experimental ; Pharmacology & Pharmacy |
WOS ID | WOS:000373550600011 |
Scopus ID | 2-s2.0-84963799701 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | DEPARTMENT OF PHARMACEUTICAL SCIENCES Institute of Chinese Medical Sciences THE STATE KEY LABORATORY OF QUALITY RESEARCH IN CHINESE MEDICINE (UNIVERSITY OF MACAU) |
Corresponding Author | Hu-Lin Jiang; Li Zong |
Affiliation | 1.China Pharmaceutical University 2.XuZhou Medical University 3.Universidade de Macau |
Recommended Citation GB/T 7714 | Feng-Zhen Wang,Lei Xing,Zheng-hai Tang,et al. Codelivery of Doxorubicin and shAkt1 by Poly(ethylenimine)-Glycyrrhetinic Acid Nanoparticles to Induce Autophagy-Mediated Liver Cancer Combination Therapy[J]. Molecular Pharmaceutics, 2016, 13(4), 1298-1307. |
APA | Feng-Zhen Wang., Lei Xing., Zheng-hai Tang., Jin-Jian Lu., Peng-Fei Cui., Jian-Bing Qiao., Lei Jiang., Hu-Lin Jiang., & Li Zong (2016). Codelivery of Doxorubicin and shAkt1 by Poly(ethylenimine)-Glycyrrhetinic Acid Nanoparticles to Induce Autophagy-Mediated Liver Cancer Combination Therapy. Molecular Pharmaceutics, 13(4), 1298-1307. |
MLA | Feng-Zhen Wang,et al."Codelivery of Doxorubicin and shAkt1 by Poly(ethylenimine)-Glycyrrhetinic Acid Nanoparticles to Induce Autophagy-Mediated Liver Cancer Combination Therapy".Molecular Pharmaceutics 13.4(2016):1298-1307. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment